Zhejiang Shapuaisi Pharmaceutical (603168.SH) obtained the drug registration certificate for sildenafil citrate orally disintegrating tablets.
Saipuaisi (603168.SH) announced that the company has recently received the "Drug Registration Certificate" for sildenafil citrate orally disintegrating tablets issued by the National Medical Products Administration.
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that recently, the company has received the "Drug Registration Certificate" for the sildenafil citrate orally disintegrating tablets issued by the National Medical Products Administration.
It is reported that the sildenafil citrate orally disintegrating tablets approved this time are used for the treatment of erectile dysfunction. As of the disclosure date of this announcement, the company's cumulative research and development investment for this drug is approximately 9.915 million yuan.
Related Articles
Hunan Gold Corporation (002155.SZ): Xilong Mining Headquarters Resumes Production.
Uber Technologies, Inc. (UBER.US) faces obstacles in its acquisition! Delivery Hero rejects the offer, causing the stock price to soar 10% and surpass the bid.
Contec Medical Systems (300869.SZ) subsidiary products have obtained EU MDR certification.
Hunan Gold Corporation (002155.SZ): Xilong Mining Headquarters Resumes Production.
Uber Technologies, Inc. (UBER.US) faces obstacles in its acquisition! Delivery Hero rejects the offer, causing the stock price to soar 10% and surpass the bid.
Contec Medical Systems (300869.SZ) subsidiary products have obtained EU MDR certification.
